European Pharmaceutical Review

OCTOBER 31, 2024

Announcement of the UK Government’s 2024 Autumn Budget on 30 October marks the first Labour budget in 14 years. It pledges to benefit key industry sectors across life sciences including R&D, innovation, manufacturing and medicine.

Manufacturing 52

Manufacturing Medical science Medicine Engineering 52

European Pharmaceutical Review

DECEMBER 28, 2023

Following their introduction, these therapies have moved to early lines of treatment, but unfortunately, a significant number of patients are not cured with these approaches. As a result, when the patient’s lymphoma relapses after treatment with chemotherapy, BV and CPIs, there are no effective treatment alternatives for these patients.

Food and Drug Administration 84

Food and Drug Administration Patients Safety Medical science 84

European Pharmaceutical Review

NOVEMBER 21, 2024

Academy of Medical Sciences. “I I am honoured to be succeeding [ Dr Mikael Dolsten ] and to be taking on leadership of a combined R&D organisation that includes… a promising pipeline of innovative medicines and vaccines candidates poised to have a tremendous impact for patients globally,” shared Dr Boshoff.

Medicine 59

Medicine Medical science Biopharma Medical 59

PM360

DECEMBER 20, 2024

When the first biosimilars were approved by the FDA almost a decade ago, they were expected to provide a cost-effective alternative to expensive biologics, improve accessibility for patients and reduce healthcare spending by creating competition in the biologic market. Overall, the findings of the analysis were positive.

Physicians 52

Physicians Marketing Competition Management 52

Pharmaceutical Technology

NOVEMBER 3, 2022

According to the agency, shortages of both drugs are expected to last until 2024, as a result of growing demand. These] are life-saving medications. And patients can die when we do not have these readily available,” he says. Here, the long-term shortages can be attributed to two factors, says Page.

Medicine 111

Medicine Manufacturing Pharmacology Healthcare 111

PM360

OCTOBER 22, 2024

Measuring medical affairs is key to driving clinical innovation, engaging scientific communities, and improving patient outcomes. To justify investment in medical affairs, it’s important to demonstrate impact and align stakeholders with different priorities. Measuring medical affairs success is challenging. References: 1.[link]

Medical 52

Medical Medical science Healthcare Healthcare 52

PM360

APRIL 22, 2024

Medical science Liaisons know that change is coming; How are they cashing in? Medical science liaisons (MSLs) within pharmaceutical companies deal in a special currency: scientific exchange and real-world insights gathering.

Education 52

Education Medical Medical science Customer Relationship Management 52